Composition:
Each Empacoza plus 10/5 mg tablet contains : Empagliflozin.......................... 10 mg.
linagliptin................................................................... 5 mg
Each Empacoza 25/5 mg tablet contains:
empagliflozin.................................................. 25 mg
Linagliptin.................................................................. 5 mg
Therapeutic Indications:
- Fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:
- To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Empacoza Plus does not provide adequate glycaemic control.
- when already being treated with the free combination of empagliflozin and linagliptin
Packaging:
Empacoza plus 10/5 mg Tablets: Box containing 3 blisters of 10 tablets.
Each Empacoza plus 25/5 mg Tablets: Box containing 3 blisters of 10 tablets each.
